Skip to main content

Technology Fitbit launches lower-cost fitness devices to combat Samsung, Apple

Fitbit unveiled the Versa Lite Edition at a media event in New York, on March 5, 2019.

Brian Ach/The Associated Press

Fitbit Inc. launched its cheapest smartwatch on Wednesday to defend its position as the second-largest seller of smartwatches after Apple Inc.

San Francisco-based Fitbit said the Versa Lite smartwatch will cost US$160, down from US$200 for the full version. While still tracking workouts and heart rate, it will lack some features such as the ability to store music directly on the watch.

In 2018, Fitbit sold 5.5 million smartwatches, behind the biggest seller Apple’s 22.5 million units, but just ahead of Samsung’s 5.3 million units, according to data firm Strategy Analytics.

Story continues below advertisement

But Samsung overtook Fitbit on a quarterly basis in the last three months of 2018.

Indeed, rivalry for a greater share of the market has heated up as Apple and Samsung have added features for health tracking, Fitbit’s core focus. The Apple Watch included an electrocardiogram feature last year, and Samsung this year added a blood pressure sensor to its Galaxy Active Watch.

Fitbit also announced new versions of its cheaper trackers in a bid to lure more casual users who might not be ready to fork out for the pricier devices of its rivals: The US$100 Fitbit HR, capable of tracking heart rate, and the US$70 Ace 2, which tracks activity in children as young as six years old.

Apple does not make a cheaper tracker and its watches start at US$279, while Samsung’s tracker and watches start at US$200.

Fitbit is trying to convince investors that it can hang on to users and sell them future devices if it gets them onto its tracking platform, which can store and share health and activity data. Chief executive James Park said at a media event ahead of the product release that the company has nearly 28 million active users.

Last month, Fitbit forecast first-quarter revenue of between US$250-million and US$268-million. That was lower than analysts’ average sales expectation of US$272.3-million, according to IBES data from Refinitiv.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter